ABSTRACT
Amyloid ß (Aß) is thought to be involved in the pathogenesis of Alzheimer's disease (AD). Aß aggregation in the brain is considered the cause of AD. Therefore, inhibiting Aß aggregation and degrading existing Aß aggregates is a promising approach for the treatment and prevention of the disease. In searching for inhibitors of Aß42 aggregation, we found that meroterpenoids isolated from Sargassum macrocarpum possess potent inhibitory activities. Therefore, we searched for active compounds from this brown alga and isolated 16 meroterpenoids, which contain three new compounds. The structures of these new compounds were elucidated using two-dimensional nuclear magnetic resonance techniques. Thioflavin-T assay and transmission electron microscopy were used to reveal the inhibitory activity of these compounds against Aß42 aggregation. All the isolated meroterpenoids were found to be active, and compounds with a hydroquinone structure tended to have stronger activity than those with a quinone structure.
Subject(s)
Alzheimer Disease , Sargassum , Terpenes , Humans , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/antagonists & inhibitors , Sargassum/chemistry , Terpenes/chemistry , Terpenes/pharmacologyABSTRACT
The structure and inhibitory activity of advanced glycation end products (AGEs) formation were studied using six model compounds and seven phlorotannins isolated from brown alga Ecklonia stolonifera. As a result, it was inferred that AGEs formation inhibitory activity was stronger when electron-rich groups were present because of the addition of many oxygen atoms to the phlorotannins.
